Authors
Ze Wang, Pengjuan Zhang, Yaping Zhang, Junhui Bai
Published in
Diabetes research and clinical practice. Pages 113638. Nov 06, 2026. Epub Nov 06, 2026.
Abstract
To explore time-varying cardiovascular effects of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and transition-specific estimates obtainable from published outcome curves.
Ten placebo-controlled cardiovascular outcome trials included 87,334 participants and eight GLP-1 RA regimens. Reconstructed major adverse cardiovascular event (MACE) data and all-cause mortality data, directly reconstructed for four trials and synthesised for four, informed a three-state model. Two trials contributed MACE data only. The model assumed no treatment effect on death before a first non-fatal MACE. Conventional random-effects meta-analysis provided a comparator.
Conventional meta-analysis yielded a MACE hazard ratio (HR) of 0.856 (95% confidence interval 0.810-0.905). Modelled transition HRs for first non-fatal MACE at 24 months ranged from 0.51 to 1.38; all 95% credible intervals included 1. Semaglutide posterior median curves suggested larger early reductions that attenuated over time. Mortality attribution depended on structural assumptions, and several sensitivity analyses showed incomplete convergence.
Conventional synthesis supported a class-level MACE reduction. Multi-state estimates suggested possible time-varying patterns but remained imprecise and assumption-dependent. These data did not establish a reliable efficacy hierarchy or empirically distinguish event prevention from post-event survival effects.
PMID:
42994759
Bibliographic data and abstract were imported from PubMed on 07 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 16
- Comments 0